Skip to main content


  • Review
  • Open Access

CGRP and migraine: neurogenic inflammation revisited

  • 1, 2Email author,
  • 1,
  • 2,
  • 2,
  • 2 and
  • 1
The Journal of Headache and Pain20056:153

  • Received: 23 February 2005
  • Accepted: 23 February 2005
  • Published:


For more than a century neurogenic inflammation has been proposed to have a role in various human diseases. The present review will cover the conceptual steps of the itinerary that has led to the conclusion that neurogenic inflammation is important in migraine. Of particular relevance for the object of this article is the observation that tachykin–independent neurogenic inflammatory responses are evident in rodents, but much less pronounced or absent in other mammal species, including man, whereas neurogenic vasodilatation, most likely mediated by CGRP, occurs in most mammalian species and also in man. Recent evidence that a CGRP receptor antagonist was effective in the treatment of migraine attack supports the hypothesis that neurogenic vasodilatation is a major underlying mechanism of migraine.

Key words

  • Calcitonin gene–related peptide
  • Neurogenic inflammation
  • Transient receptor potential vanilloid–1
  • Migraine
  • Vasodilatation


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.